meibomian gland dysfunction
01.19.21
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)Source: Bausch + Lomb
11.24.20
Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027Source: Grand View Research, Inc.
11.24.20
Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDSource: Bausch Health Companies Inc.
10.22.20
Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland DysfunctionSource: Azura Ophthalmics
10.01.20
New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian GlandsSource: TearRestore
09.09.20
Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCareSource: Sight Sciences
06.13.19
First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry EyeSource: Sight Sciences
05.29.19
Quantel Medical Receives CE Mark for Dry Eye Treatment Platform Lacrystim IPLSource: Quantel Medical